Cognitive functioning Clinically important change in cognitive functioning as defined by each study · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · people with treatment‐resistant schizophrenia
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Service outcomes: Hospitalisation · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event/effect(s) ‐ death · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · people with treatment‐resistant schizophrenia
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use (short term) ‐ hospitalisation (number readmitted) · people with treatment‐resistant schizophrenia
ECT plus standard care may leads to lower service use (short term) ‐ hospitalisation (number readmitted) compared with sham‐ECT plus standard care (low certainty).
1 finding from 1 review
Adverse event/effect(s) ‐ death · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response to treatment (medium term) Clinically important response to treatment as defined by each study · people with treatment‐resistant schizophrenia
ECT plus standard care showed no clear difference in response to treatment (medium term) Clinically important response to… compared with antipsychotics plus standard care (low certainty).
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes global state: any change in global state – unspecified problem… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: change in hospital status – any change · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes service use: change in hospital status – any change compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review